Highlighting Pharvaris' Breakthrough Research in HAE
Switzerland based Pharvaris, a promising late-stage biopharmaceutical company, is making significant strides in transforming the treatment landscape for hereditary angioedema (HAE). With a focus on developing innovative oral bradykinin B2 receptor antagonists, they are showcasing their clinical and non-clinical data at a prestigious scientific meeting, solidifying their commitment to improving patient outcomes.
Introducing Deucrictibant: A Potential Game Changer
Deucrictibant stands out as a notable oral small-molecule antagonist targeting the bradykinin B2 receptor. By inhibiting this receptor, it is designed to prevent HAE attacks and manage symptoms when they occur. Pharvaris has innovatively formulated two types of deucrictibant: an extended-release tablet for ongoing prophylactic treatment and an immediate-release capsule for quick relief during HAE attacks.
Clinical Evidence Supporting Efficacy
At the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), Pharvaris is set to present compelling data from several studies, emphasizing the robustness of deucrictibant's efficacy and safety. Key findings from the CHAPTER-1 Phase 2 trial reveal the drug's remarkable ability to reduce the median percentage of days a patient experiences symptoms, dropping from 14.6% with a placebo to just 1.7% when taking 40 mg/day of deucrictibant, as highlighted by Dr. H. James Wedner.
Ongoing Studies and Future Directions
Furthermore, the ongoing CHAPTER-1 open-label extension study reinforces the long-term safety and efficacy of deucrictibant, showing that about 80% of participants achieved a staggering 90% decrease in their attack rates compared to their baseline. These results bolster Pharvaris' confidence in advancing both their prophylactic and on-demand treatment strategies.
Predictive Models Backing Clinical Outcomes
Pharvaris has utilized nonclinical data derived from bradykinin (BK) challenge models in non-human primates to support their clinical findings. This data has played a crucial role in successfully predicting the pharmacokinetics and pharmacodynamics of deucrictibant in humans, thereby aligning well with their ongoing Phase 2 trials.
A Commitment to Patient-Centric Solutions
Pharvaris' overarching goal is to provide effective, well-tolerated alternatives for individuals living with HAE. They are actively enrolling participants in a pivotal Phase 3 study for immediate treatment of HAE attacks and are poised to commence another pivotal study aimed at the drug's preventative capabilities by year-end.
About Pharvaris
Pharvaris continues to demonstrate its dedication to revolutionizing HAE treatment through scientifically-backed solutions and thorough research. Their aim is to offer comprehensive management options for patients requiring therapeutic intervention for HAE, thereby changing lives for the better.
Contact Information
If you wish to learn more about Pharvaris or their innovative drug developments, you can reach out to:
Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
maggie.beller@pharvaris.com
Frequently Asked Questions
What is Deucrictibant?
Deucrictibant is a novel oral bradykinin B2 receptor antagonist developed by Pharvaris, designed to prevent and treat hereditary angioedema (HAE) attacks.
What are the key findings from the CHAPTER-1 Phase 2 study?
The Phase 2 study showed that deucrictibant significantly reduced the median percentage of days with symptoms from 14.6% to 1.7% in patients taking 40 mg/day.
How effective is Deucrictibant in reducing attack rates?
According to ongoing studies, approximately 80% of participants experienced at least a 90% reduction in attack rates compared to their baseline.
What stages of clinical development is Pharvaris currently in?
Pharvaris is currently enrolling participants for a pivotal Phase 3 study for on-demand treatment and plans to initiate another pivotal Phase 3 study for prophylactic treatment soon.
Where can I learn more about Pharvaris?
More information can be accessed through the Pharvaris website, which outlines their projects and corporate developments.
